about
T cells with a CD4+CD25+ regulatory phenotype suppress in vitro proliferation of virus-specific CD8+ T cells during chronic hepatitis C virus infection.Virus-Specific CD8+ Lymphocytes Share the Same Effector-Memory Phenotype but Exhibit Functional Differences in Acute Hepatitis B and CPD-1 Expression in Acute Hepatitis C Virus (HCV) Infection Is Associated with HCV-Specific CD8 ExhaustionEx vivo characterization of tumor-derived melanoma antigen encoding gene-specific CD8+cells in patients with hepatocellular carcinomaGenome-wide meta-analyses identify three loci associated with primary biliary cirrhosisContribution of herpesvirus specific CD8 T cells to anti-viral T cell response in humans.Immunological and molecular correlates of disease recurrence after liver resection for hepatocellular carcinoma.Activation of natural killer cells during acute infection with hepatitis C virus.Comparative pathogenesis of HBV and HCV.Viral determinants and host immune responses in the pathogenesis of HBV infection.Kinetics of the immune response during HBV and HCV infection.Role of viral and host factors in HCV persistence: which lesson for therapeutic and preventive strategies?Cytotoxic T lymphocyte response to a wild type hepatitis B virus epitope in patients chronically infected by variant viruses carrying substitutions within the epitope.Is there a role for immunotherapy in hepatocellular carcinoma?Host ethnicity and virus genotype shape the hepatitis B virus-specific T-cell repertoire.Mobilizing monocytes to cross-present circulating viral antigen in chronic infection.Treatment of chronic hepatitis B: update of the recommendations from the 2007 Italian Workshop.Bariatric surgery in patients with inflammatory bowel disease: an accessible path? Report of a case series and review of the literature.HBV and the immune response.Interleukin 28B polymorphisms as predictors of sustained virological response in chronic hepatitis C: systematic review and meta-analysis.Natural killer cell phenotype modulation and natural killer/T-cell interplay in nucleos(t)ide analogue-treated hepatitis e antigen-negative patients with chronic hepatitis B.Viral mutations, TCR antagonism and escape from the immune response.Natural killer cells phenotypic characterization as an outcome predictor of HCV-linked HCC after curative treatments.Randomized phase II study of GS-4774 as a therapeutic vaccine in virally suppressed patients with chronic hepatitis B.Gene expression analysis during acute hepatitis C virus infection associates dendritic cell activation with viral clearance.Development and validation of a nomogram based on clinical factors and standard laboratory tests for prediction of clinically significant liver fibrosis in chronic hepatitis C virus infection.Characterization of hepatitis B virus (HBV)-specific T-cell dysfunction in chronic HBV infectionLack of full CD8 functional restoration after antiviral treatment for acute and chronic hepatitis C virus infection.Combined blockade of programmed death-1 and activation of CD137 increase responses of human liver T cells against HBV, but not HCV.Conserved hepatitis C virus sequences are highly immunogenic for CD4(+) T cells: implications for vaccine development.The influence of T cell cross-reactivity on HCV-peptide specific human T cell response.Outcome of acute hepatitis C is related to virus-specific CD4 function and maturation of antiviral memory CD8 responses.Risk factors and outcome among a large patient cohort with community-acquired acute hepatitis C in Italy.Predicting treatment outcome following 24 weeks peginterferon alpha-2a/ribavirin therapy in patients infected with HCV genotype 1: utility of HCV-RNA at day 0, day 22, day 29, and week 6.Hepatitis C virus viremia following clinical resolution of acute hepatitis C.Intrahepatic and circulating HLA class II-restricted, hepatitis C virus-specific T cells: functional characterization in patients with chronic hepatitis C.Restoration of HCV-specific T cell functions by PD-1/PD-L1 blockade in HCV infection: effect of viremia levels and antiviral treatment.Lamivudine treatment can overcome cytotoxic T-cell hyporesponsiveness in chronic hepatitis B: new perspectives for immune therapy.Treatment optimization and prediction of HCV clearance in patients with acute HCV infection.The characteristics of the cell-mediated immune response identify different profiles of occult hepatitis B virus infection.
P50
Q27469830-7D776586-9463-4176-9734-E9D97AC726ABQ27472920-0CA35F47-3C25-41DC-80CF-2E6C17A65F4FQ27477628-3DCC985E-4E61-4971-AAC2-D0A4E29617BFQ28191190-0E7CA480-7498-47B8-B9EB-5F9F0CFEBE1CQ28943317-3992F3CA-46F5-47F1-8D20-4F1EB678AF81Q33680736-2A80B10F-205A-461A-8D65-C50CA42E74A2Q34187221-0F003E52-220D-491D-B7DC-3C8A420D199DQ34283615-CA16E654-CF22-461B-8603-77A2F20C613AQ34556313-C288E6C2-D545-48BE-8E6E-528354A8DF84Q34737124-B0CDCAB3-03AC-42B6-84E2-1B6D42998D04Q35164171-F32D497F-FC9C-4EF1-BA90-1C203F76B622Q35967086-832B7A8B-65A4-4C9D-86D4-003934AA429EQ36363678-87428ADD-6B01-4D0D-AAB2-B181E7838E96Q36388228-99070153-645C-49AB-B249-7FD25449D220Q36949834-A97061B1-FF76-4FBC-83C9-2B949100A510Q37123862-7932C7D2-78A9-4432-B1C7-DE2C4FF4FA59Q37833228-2CFDBB17-5DCA-4C40-BFAF-10A29DD5CF2AQ38291946-42CA1491-7496-49F7-8A8A-D12E2DDF549BQ38295864-367F5DF0-FAE6-4309-878E-E9EBEE84427EQ38445623-89BBEEC2-D14B-4A3C-9BDA-A4478DB0C155Q38964920-21DD8C43-984E-4484-B7FA-BF10464291E6Q40380488-5B494278-27ED-48A2-A133-A708054260E8Q40542458-2E5ACD48-CE90-4C21-A6F1-DE7E284CE76CQ40664637-71538CDC-0B3E-4FAF-B860-72F3C9D37BCDQ40961624-1E479286-8AE5-4E2E-AC6A-A654D02F522BQ42255787-68ADE7AB-D7F9-4B2A-A65A-09AAB5DB6493Q42797242-28B4A7FB-D951-4DA6-B922-2189DC97BE17Q42977777-9E6B402C-5471-4F38-B245-2A9489D34498Q42983710-8DA2E81A-9C1D-4AB4-92A0-B12F0028FCAFQ42995350-58069717-74F2-491E-B875-8101C1BE7B84Q42998497-DB3F0B7A-7360-46D5-84F0-EAB02610EE65Q43000889-F6AF4D90-6403-4966-AD39-11BA61F67AC9Q43032166-E6692D71-ADBD-4512-8CE1-199E3AC73FDEQ43034678-A1138931-F949-4322-A5A5-22B1C479062DQ43036071-4C729BFF-DA09-401E-A1AC-B167A063ED87Q43037625-59097E73-5722-4E64-ABF9-C577949FF451Q43046903-FA0F0342-3FA6-4E83-83BB-64C3E2617991Q43563104-39220CCD-DE4A-43FE-A980-8CFBCA6C216EQ43959499-B8686F0D-DD87-42E1-B311-2D67D189579FQ43974120-1F9E7AE4-A327-4D28-940F-DDCB84795C0A
P50
description
Forscher
@de
chercheur
@fr
investigador
@es
researcher
@en
ricercatore
@it
wetenschapper
@nl
研究者
@zh
name
Ferrari C
@ast
Ferrari C
@en
Ferrari C
@es
Ferrari C
@nl
type
label
Ferrari C
@ast
Ferrari C
@en
Ferrari C
@es
Ferrari C
@nl
prefLabel
Ferrari C
@ast
Ferrari C
@en
Ferrari C
@es
Ferrari C
@nl
P31
P496
0000-0002-7843-4963